Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Fisher Asset Management LLC

Fisher Asset Management LLC lowered its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 1.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 186,428 shares of the medical research company’s stock after selling 2,272 shares during the period. Fisher Asset Management LLC owned about 0.36% of Charles River Laboratories International worth $44,072,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the business. abrdn plc grew its holdings in Charles River Laboratories International by 872.0% during the 4th quarter. abrdn plc now owns 121,807 shares of the medical research company’s stock valued at $28,795,000 after buying an additional 109,275 shares during the last quarter. Regency Capital Management Inc. DE acquired a new stake in shares of Charles River Laboratories International during the 4th quarter worth about $3,703,000. WCM Investment Management LLC purchased a new stake in shares of Charles River Laboratories International during the fourth quarter worth about $1,396,000. DekaBank Deutsche Girozentrale raised its position in shares of Charles River Laboratories International by 98.6% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 14,094 shares of the medical research company’s stock valued at $3,333,000 after buying an additional 6,997 shares during the last quarter. Finally, AMG National Trust Bank acquired a new stake in Charles River Laboratories International during the third quarter worth approximately $1,119,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on CRL. Guggenheim cut Charles River Laboratories International from a “buy” rating to a “neutral” rating in a report on Thursday, February 15th. UBS Group lifted their price target on Charles River Laboratories International from $270.00 to $290.00 and gave the company a “buy” rating in a report on Thursday, February 15th. Robert W. Baird increased their price objective on shares of Charles River Laboratories International from $252.00 to $268.00 and gave the stock an “outperform” rating in a report on Thursday, February 15th. TheStreet upgraded shares of Charles River Laboratories International from a “c+” rating to a “b-” rating in a report on Friday, March 1st. Finally, Argus upped their price target on shares of Charles River Laboratories International from $240.00 to $290.00 and gave the stock a “buy” rating in a research report on Monday, March 18th. Five analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $253.23.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Shannon M. Parisotto sold 5,882 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the sale, the executive vice president now directly owns 2,596 shares in the company, valued at approximately $626,155.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, EVP Shannon M. Parisotto sold 5,882 shares of the business’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $241.20, for a total value of $1,418,738.40. Following the completion of the sale, the executive vice president now directly owns 2,596 shares of the company’s stock, valued at $626,155.20. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP William D. Barbo sold 4,050 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $248.50, for a total value of $1,006,425.00. Following the completion of the transaction, the vice president now owns 22,879 shares of the company’s stock, valued at approximately $5,685,431.50. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 14,932 shares of company stock valued at $3,693,663. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Stock Performance

Shares of NYSE:CRL opened at $233.47 on Friday. The business’s 50-day simple moving average is $252.23 and its 200 day simple moving average is $223.97. The company has a market cap of $12.03 billion, a P/E ratio of 25.35, a PEG ratio of 1.80 and a beta of 1.44. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.16 and a current ratio of 1.52. Charles River Laboratories International, Inc. has a one year low of $161.65 and a one year high of $275.00.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.39 by $0.07. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $991.25 million. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. The business’s quarterly revenue was down 7.9% on a year-over-year basis. During the same quarter last year, the firm posted $2.98 earnings per share. On average, sell-side analysts forecast that Charles River Laboratories International, Inc. will post 11.01 earnings per share for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).